202415-95-0

Usage

Uses

Used in Pharmaceutical Applications:
(3S,5S,6R,7R,8R,9S,10R,13S,14S)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-one is used as a pharmaceutical agent for its potential biological activities and applications in hormonal regulation and medicinal chemistry. Its unique structure and functional groups allow it to interact with various biological targets and pathways, making it a promising candidate for the development of new drugs and therapies.
Further analysis and research are required to fully understand and utilize the properties and potential uses of this chemical compound in different industries and applications.

Upstream product

• 53-43-0 dehydroepiandrosterone 
• 7745-40-6 3β-hydroxy-17,17-ethylenedioxo-5-androstene 
• 202415-78-9 5-androsten-3β,7β-diol-17-one ethylene ketal 3-tert-butyldimethylsilyl ether 
• 202415-94-9 (3S,5S,6R,7R,8R,9S,10R,13S,14S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolane]-3,6,7-triol 
• 769959-84-4 C₂₁H₃₂O₄ 
• 166173-97-3 (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,3,4,8,9,10,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-7(2H)-one 
• 202415-77-8 5-androsten-7,17-dione-3β-ol ethylene ketal tert-butyldimethylsilyl ether 
• 202415-76-7 tert-butyl(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-3-yl)oxy)dimethylsilane 
• 202415-66-5 5α-androstan-17-one-3β,6α,7β-triol ethylene ketal 3-tert-butyldimethylsilyl ether 

Relevant academic research and scientific papers

An improved and efficient synthesis for IPL576,092 and its analogues

An improved and efficient preparation of IPL576,092 was developed. The synthetic route involves selective allylic oxidation of a? 5-sterols and subsequent hydroboration-oxidation as the key steps. In addition, two analogues were readily synthesized from commercially available steroidal compounds in two steps in the same way.

Efficient synthesis of IPL576,092: a novel anti-asthma agent.

An enantioseletive synthesis of the novel anti-asthma agent IRL576,092 (2) is described. The synthetic route developed involves stereoselective 1,2-reduction of the enone carbonyl functionality of 6 and subsequent hydroboration as the key steps. Starting from the commercially available 5-androsten-3beta-ol-17-one 3, this approach affords IPL576,092 (2) in nine steps with overall yields of 25%, employing a limited number of chromatographic steps.

SYNTHESIS OF A SUBSTITUTED INDENE DERIVATIVE

This invention is directed to methods of preparing AQX-1125 having the formula: This invention is also directed to intermediates utilized in the methods of preparing AQX-1125.